Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane in Autism
NCT02677051Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Feb 2016
- Primary completion
- Dec 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Placebo with Sulforaphane (2 arms). Primary endpoints: Aberrant Behavior Checklist at 22 weeks, Social Responsiveness Scale at 22 weeks and 2 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
sulforaphane
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02677051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677051.